Laurus Labs advances after completion of USFDA inspection

Image
Capital Market
Last Updated : Jun 17 2019 | 1:16 PM IST

Laurus Labs rose 2.01% to Rs 345.50 at 11:37 IST on the BSE after the company said that no data integrity issues were observed in the inspection concluded by the US drug regulator at Visakhapatnam units.

Meanwhile, the S&P BSE Sensex was down by 239.15 points, or 0.61% to 39,212.92.

On the BSE, 2125 shares were traded in Laurus Labs counter so far compared with average daily volumes of 3676 shares in the past two weeks. The stock had hit a high of Rs. 350.80 and a low of Rs 339.80 so far during the day. It hit a 52-week high of Rs. 515 on 15 June 2018 and a 52-week low of Rs. 324 on 18 February 2019.

Laurus Labs announced after market hours on Friday, 14 June 2019, that the US Food and Drug Administration (USFDA) completed inspection of Active Pharmaceutical Ingredient (API) facilities in units 1 & 3 at Parawada, Visakhapatnam, Andhra Pradesh, with two observations.

The company stated that the observations are procedural in nature. It was a regular surveillance audit by USFDA, and no data integrity issues were observed in the inspection.

On a consolidated basis, Laurus Labs' net profit fell 4.21% to Rs 43.18 crore on a 13.37% rise in net sales to Rs 635.16 crore in Q4 March 2019 over Q4 March 2018.

Laurus Labs is a fully integrated pharmaceutical company in India.

Powered by Capital Market - Live News

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Jun 17 2019 | 11:44 AM IST

Next Story